Medicare paid 77 percent more for brand-name drugs over a five-year span, despite a 17 percent drop in the number of medicines prescribed, an inspector general study found.

The study from the Department of Health and Human Services’ watchdog looked at the impact of high drug prices on costs for Medicare Part D, the program’s prescription drug plan. It comes as the Trump administration is attempting to contain drug costs in the health insurance program for seniors.

Recommended Stories

Eli Lilly opposes using imports to tackle high drug prices

Cancer groups approach drug price overhaul with caution

Medicare could have saved nearly $1 billion by using generics, study finds